Author: Sakthivel, Priya

Source: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Volume 3, Number 3, November 2009 , pp. 205-213(9)

Publisher: Bentham Science Publishers

Abstract:

Inducible Co-stimulator (ICOS) is one of the co-stimulatory molecules that are unregulated within hours after TCR engagement. The interaction between ICOS and its ligand ICOSL positively co-stimulates T cell activation and proliferation. Thus, ICOS/ICOSL pathway contributes to one of the predisposing factors for autoimmune condition. Therefore, the positive co-stimulatory properties of ICOS are now being regarded as a possible and potential target for treating autoimmune disorders. Several in vivo studies have confirmed the amelioration of autoimmune disease by targeting ICOS pathway. This mini-review comprehensively describes the updated issues regarding ICOS from their discovery and functional consequences (at both genetic and protein aspects) to the recent patents in targeting ICOS pathway for turning-off immune responses in autoimmunity.

Keywords: ICOS; ICOSL (B7RP-1); co-stimulatory molecules; autoimmune disease

Document Type: Research article

Publication date: 2009-11-01

More about this publication?

• Recent Patents on Endocrine, Metabolic & Immune Drug Discovery publishes review articles by experts on recent patents in the field of endocrine, metabolic and immune drug discovery e.g. on novel bioactive compounds, analogs & targets. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in endocrine, metabolic and immune drug design and discovery.

Related content

• In this: publication
• By this: publisher
• In this Subject: Allergy & Immunology ,  Pharmacology
• By this author: Sakthivel, Priya

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers